Liver impairment drug study completed: what happens to BPN14770?
NCT ID NCT07018492
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how the drug BPN14770 is handled by the body in people with mild, moderate, or severe liver impairment compared to healthy people. A total of 32 adults took a single dose of the drug. Researchers measured drug levels in the blood and checked for side effects. The goal was to understand if liver problems change how the drug works, which is important for future safe use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BPN14770
What this could lead to
If successful, this study will help determine safe dosing of BPN14770 for people with liver problems, potentially guiding future treatment use.
What could go wrong
This is an early phase 1 study with only 32 people. It focuses on drug processing, not on treating any disease, so it may not lead to a new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division of Clinical Pharmacology, University of Miami
Miami, Florida, 33136, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Texas Liver Institute
San Antonio, Texas, 78215, United States